Summary
New treatment regimens utilizing combinations of protease (nonstructural protein 3-4A [NS3-4A]), nucleotide (NS5B), nonnucleoside (NS5B), and NS5A inhibitors are successfully being used to treat patients with hepatitis C virus coinfected with HIV. Sustained virologic response rates of ≥ 90% are achieved after 12 to 24 weeks in patients with and without cirrhosis who are treatment naïve and experienced. HIV is no longer a predictor of poorer response to hepatitis C virus therapy.
- hepatitis C virus
- HIV
- genotypes
- fibrosis
- sustained virologic response
- antiretroviral therapy
- coinfectious diseases
- hepatic decomposition
- gastroenterology guidelines
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.